Allogeneic HSCT from an unrelated volunteer is largely employed to treat children with ALL in second CR. We analyzed the outcome of patients transplanted in Centers belonging to the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) between 1995 and 2009. The outcome of children with 2nd CR ALL has significantly improved over time, due to a reduction of TRM. Limited severity acute and chronic GVHD protect from leukemia recurrence. BFM classification of 1st relapse predicts outcome.

Outcome of children with ALL in second CR transplanted from an unrelated donor has significantly improved over time and is favourably influenced by the occurrence of grade I-II acute GVHD and limited chronic GVHD

MORETTA, Francesca;
2013-01-01

Abstract

Allogeneic HSCT from an unrelated volunteer is largely employed to treat children with ALL in second CR. We analyzed the outcome of patients transplanted in Centers belonging to the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) between 1995 and 2009. The outcome of children with 2nd CR ALL has significantly improved over time, due to a reduction of TRM. Limited severity acute and chronic GVHD protect from leukemia recurrence. BFM classification of 1st relapse predicts outcome.
Allogeneic HSCT, Acute Lymphoblastic Leukemia, bone marrow transplantation , GVHD
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/936015
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact